MedTrace Logo

Large-scale COVID-19 Population Screening

NCT04847804 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2023-03-01

No results posted yet for this study

Summary

Infectious diseases pose a threat to the life of individuals worldwide. The pandemic has highlighted the need to develop an innovative and cost- effective large population-based screening methodology. The investigators propose a two-fold improvement barcode-labeled testing strategy specifically for pooled samples. This platform combines isothermal amplification and real-time electrochemical detection; electroactive modified loop probes will be used in the amplification step for barcode readout. This method enables four samples pooled detection at the same time. This platform will be integrated into a disposable microfluidic chip that allows minimal human intervention during the process to realize a massively parallel screening platform for infectious disease pathogens.

Objectives

1. To develop a sensing method for concurrent electrochemical-tag coded isothermal amplification and real-time electrochemical detection;
2. To design a molecular strategy to barcode four individual samples so that they can be pooled together and to simultaneously amplify and identify a positive individual, if any, from the pooled sample.
3. To fabricate a microfluidic device integrating the sample processor and barcoding module with the nucleic acid amplification and detection step for large-scale population screening of up to 100 individuals.
4. To validate the performance of the prototype using clinical specimens and benchmark it against the detection data from commercially available testing equipment.

Conditions

  • Covid19

Sponsors & Collaborators

  • Chinese University of Hong Kong

    collaborator OTHER

  • Prince of Wales Hospital, Shatin, Hong Kong

    collaborator OTHER

  • Hong Kong University of Science and Technology

    lead OTHER

Principal Investigators

  • I-Ming HSING · Hong Kong University of Sciences and Technology

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-07-01
Primary Completion
2024-05-31
Completion
2024-05-31

Countries

  • Hong Kong

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04847804 on ClinicalTrials.gov